Cystic fibrosis physicians’ perspectives on the timing of referral for lung transplant evaluation: a survey of physicians in the United States

Table 3 Colonization with specific organisms that would prevent referral for lung transplant evaluation, grouped by Program type

	All Respondents^a N = 114	Adult Programs N = 57	Affiliate Programs N = 12	Pediatric Programs N = 43
	n (%)	n (%)	n (%)	n (%)
Burkholderia cenocepacia	63 (55%)	37 (65%)	7 (58%)	17 (40%)
Mycobacterium abscessus	25 (22%)	10 (18%)	4 (33%)	11 (26%)
Burkholderia cepacia complex	24 (21%)	15 (26%)	2 (17%)	7 (16%)
Mycobacterium avium complex (MAC)	6 (5%)	3 (5%)	0	3 (7%)
Multidrug resistant bacteria^b	3 (3%)	1 (2%)	0	2 (5%)
Aspergillus fumigatus	1 (1%)	1 (2%)	0	0
Skipped question^c	36 (32%)	16 (28%)	3 (25%)	17 (40%)

^aTwo respondents did not report Program type
^bMultidrug resistant bacteria, including: Pseudomonas aeruginosa, Staphylococcus aureus, Stenotrophomonas maltophilia, Alcaligenes xylosoxidans
^cAssumption: none of these would prevent referral for lung transplant evaluation

ISSN: 1471-2466